2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, AIDS-Related
1
HIV Infections
1
Dendritic Cell Sarcoma, Interdigitating
1
B-cell Tumors
1
Interventions
Doxorubicin
20
Vincristine
17
Zidovudine
13
Cyclophosphamide
12
Bleomycin
12
Etoposide
10
Rituximab
6
Prednisone
6
Interferon alpha-2
6
Cytarabine
6
Polymerase Chain Reaction
5
Liposomes
5
Filgrastim
5
Dexamethasone
5
Biopsy
5
tecogalan
4
sargramostim
4
Specimen Handling
4
Methotrexate
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
4
Fluorouracil
4
Peripheral Blood Stem Cell Transplantation
3
Paclitaxel
3
Nivolumab
3
interferon alfa-n1
2
fludarabine phosphate
2
fludarabine
2
cabozantinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HIV Infections
×
efavirenz
×
Clear all
NCT00799136
2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2
Completed
6 enrolled